Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...

The first Saturday of May each year marks World Ankylosing Spondylitis (AS) Day, raising awareness of the 54 million patients ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer’s morning show.

You have full access to this article via your institution. Lilly will acquire Verve Therapeutics and a pipeline of one-time treatments for cardiovascular diseases in a deal worth up to US$1.3 ...

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.

In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:LLY), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...